Ginkgo Bioworks
DNA
348 hedge funds and large institutions have $2.25B invested in Ginkgo Bioworks in 2023 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 139 increasing their positions, 58 reducing their positions, and 17 closing their positions.
229% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 17
140% more repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 58
10% more funds holding
Funds holding: 315 → 348 (+33)
2% more call options, than puts
Call options by funds: $7.89M | Put options by funds: $7.78M
0.03% more ownership
Funds ownership: 1.91% → 1.94% (+0.03%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less capital invested
Capital invested by funds: $2.25B → $2.25B (-$5.08M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$24.9M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$15.9M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$15.9M |
| 4 |
WF
Welch & Forbes
Boston,
Massachusetts
|
+$14M |
| 5 |
BlackRock
New York
|
+$8.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GA
General Atlantic
New York
|
-$60.1M |
| 2 |
TCM
Trybe Capital Management
Greenwich,
Connecticut
|
-$7.03M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$6.92M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$4.54M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.67M |
DNA Hedge Fund Activity: Q3 2023 in Review
348 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks (DNA) for Q3 2023, worth a combined $2.25B — down 0.23% from $2.25B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new DNA positions and 17 closed out — a net gain of 39 holders — while 139 added to existing stakes and 58 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $24.9M. The largest seller was General Atlantic, exiting entirely with an estimated $60.1M sold.
- 348 institutional investors held Ginkgo Bioworks (DNA) as of Q3 2023, up from 315 in Q2 2023.
- Funds reported $2.25B of Ginkgo Bioworks stock for Q3 2023, down 0.23% quarter-over-quarter.
- 56 funds opened new Ginkgo Bioworks positions in Q3 2023 and 17 closed out, a net change of +39 holders.
- The largest Ginkgo Bioworks buyer in Q3 2023 was ARK Investment Management, an estimated $24.9M added.
- The largest Ginkgo Bioworks seller in Q3 2023 was General Atlantic, an estimated $60.1M sold.
Based on aggregated 13F filings for Q3 2023.